Pemafibrate

佩玛贝特

Report date: 2026/04/11 20:00:19
NME

Base Information

Drug NamePemafibrate
Drug Alias Name培马贝特pemafibratopemafibratum佩玛贝特Parmodia +[13] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPeroxisome proliferator-activated receptor α agonists
TargetsPeroxisome proliferator-activated receptor α
Therapy Area/IndicationsDiabetic macular oedemaFibrosisHypertriglyceridemia +[10] 
Global Approved IndicationsHyperlipidemias
Approved Indications in ChinaHyperlipidemias
Original Approved Country/TerritoryJapan
Original Approved Date2017/07/03
Country/TerritoryCzechiaBulgariaCanada +[28] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesKowa Dental Health Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesKowa Company LtdKowa Research Institute IncKowa Company, Ltd., Nagoya Factory +[6] 
Inactive CompaniesJaeb Center For Health Research Inc
Active IndicationsFibrosisHyperlipidemiasDyslipidemias +[5] 
Inactive IndicationsDiabetic macular oedemaHypertriglyceridemiaDiabetes Mellitus, Type 2 +[5] 

Other Information

ATC CodeC10AB
Related LinksWikipediaDrugBankKEGG